Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Methods Of Healthcare Delivery System01:26

Methods Of Healthcare Delivery System

At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
Global Regulatory Systems01:28

Global Regulatory Systems

Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered GABA and secondary bile acids in Guillain-Barré syndrome: association with gut dysbiosis.

Frontiers in immunology·2026
Same author

SFRP2 drives aerobic glycolysis and tumor progression in ovarian cancer by transcriptional upregulation of PTK2B.

Journal of translational medicine·2026
Same author

A clinical study of the CALLY index and HALP score for evaluating response to FOLFOX in colorectal cancer with lung metastases.

American journal of translational research·2026
Same author

HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy.

Cell death discovery·2026
Same author

Embedding Kolb's experiential learning cycle in biotechnology education: a scientific experience before learning model.

BMC medical education·2026
Same author

Corylifol A alleviates rheumatoid arthritis by targeting HSP90α and suppressing Wnt/β-catenin signaling.

Biochemical pharmacology·2026

Related Experiment Video

Updated: Jun 2, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

The "China model" for rare disease governance: Policy framework, local implementation, and pathways for optimization.

Xiumei Zhang1, Jing Luan2, Yan Mu1

  • 1School of Healthcare Security, Shandong First Medical University & Shandong Academy of Medical Science, Ji'nan, Shandong, China.

Intractable & Rare Diseases Research
|June 1, 2026
PubMed
Summary

China

Keywords:
China modelcase registrationcollaborative network for diagnosis and treatmentdrug accessibilitymedical securityrare diseases

More Related Videos

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Related Experiment Videos

Last Updated: Jun 2, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Area of Science:

  • Public Health
  • Health Policy
  • Rare Diseases

Background:

  • Global challenges in rare disease diagnosis and treatment persist.
  • China developed a unique "China Model" for rare disease governance.
  • This model emphasizes national policy and coordinated local action.

Purpose of the Study:

  • To systematically review China's rare disease policies from 2009-2026.
  • To analyze key domains: prevention, list-based governance, diagnosis, treatment, drug access, and payment.
  • To examine Shandong Province as a case study.

Main Methods:

  • Systematic review of national and provincial rare disease policies.
  • Analysis of five core governance domains.
  • Case study of Shandong Province's implementation.

Main Results:

  • Unified standards via two national rare disease lists (207 conditions).
  • 126 treatments included in national medical insurance.
  • Shandong Province integrated systems and developed multilevel payment mechanisms.

Conclusions:

  • China's "China Model" enhances clinical capacity via standardized systems and networks.
  • Multilevel risk-sharing mechanisms are central.
  • Persistent challenges include policy coordination, drug access, and data infrastructure.